IQVIA, Illumina, Mayo Clinic, and ARK Labs leverage NVIDIA AI and accelerated computing to transform $10 trillion healthcare and life sciences industry
JPMorgan Healthcare Conference — NVIDIA today announced its commitment to transform the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research, and pioneering advanced healthcare services with agent and generative AI. We have announced a new partnership.
The convergence of AI, high-speed computing, and biological data is transforming healthcare into the largest technology industry. Healthcare leaders IQVIA, Illumina, Mayo Clinic, and Arc Institute use the latest NVIDIA technology to develop solutions that help improve human health.
These solutions include AI agents that can reduce administrative burden and speed clinical trials; AI models that learn from biological instruments to advance drug discovery and digital pathology; includes physical AI robots. AI agents, AI equipment, and AI robots will help address $3 trillion in operations dedicated to supporting industry growth and create opportunities for a multi-hundred billion dollar AI factory.
NVIDIA's Vice President of Healthcare, Kimberly Powell, said: “AI presents an incredible opportunity to advance healthcare and life sciences by giving healthcare providers the tools to detect diseases earlier and discover new treatments faster.” “NVIDIA AI and Accelerators By combining our rated computing capabilities with the expertise of industry leaders, we are poised to usher in a new era of medical and biological innovation to improve patient outcomes around the world.”
AI foundry services accelerate drug and medical device development
IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries, with over 64 petabytes combined with its deep domain using NVIDIA AI Foundry services. Building custom foundational models on information. Expertise. The company also develops agent AI solutions powered by NVIDIA AI enterprise software, including NVIDIA NIM™ microservices and NVIDIA Blueprints, to accelerate research, clinical development, and access to new treatments. IQVIA is a leader in the responsible use of AI, ensuring its AI-powered capabilities are based on privacy, regulatory compliance, and patient safety.
said Bhavik Patel, President of Commercial Solutions at IQVIA. “We are combining our industry-leading capabilities and 10 years of experience in artificial intelligence with NVIDIA’s advanced AI technology to create a system that is trained on world-class medical information and optimized for life sciences workflows. We are excited to build new solutions powered by AI agents. This collaboration advances our mission to help our clients accelerate innovation and bring therapeutics to market.”
Illumina and NVIDIA accelerate the next era of genomic breakthroughs
Illumina, a global leader in DNA sequencing and informatics technology, is collaborating with NVIDIA to unlock the next generation of genomics for drug discovery and human health.
The partnership will enable Illumina to use NVIDIA accelerated computing and AI toolsets for multi-omics analysis software and workflows. This will make the analysis of the human genome and the insights it provides more accessible to researchers, pharmaceutical companies, and other life sciences customers.
Illumina offers DRAGEN analytics software on NVIDIA accelerated computing within the Illumina Connected Analytics Platform. This integration is designed to expand access to DRAGEN globally, wherever NVIDIA's computing platforms exist.
Over the past five years, single-cell and spatial genomics have revolutionized drug discovery by providing unprecedented insight into the understanding of cells. To further expand the genomics market and enable breakthroughs in target identification, clinical development, and biomarker discovery, NVIDIA and Illumina are developing new biologically-based models and integrating multi-omics technology on the Illumina Connected Analytics Platform. We plan to collaborate to advance data analysis.
The research and development community can leverage rich genomic data by integrating NVIDIA RAPIDS™ high-speed data science software included in the NVIDIA AI Enterprise software platform with the generative AI model and proprietary dataset fine-tuning capabilities of the NVIDIA BioNeMo™ platform. It's faster and easier to leverage. MONAI for spatial cell imaging workflows. Illumina and NVIDIA are working to make these tools accessible on the Illumina Connected Analytics Platform.
“Our ability to combine the power of AI with multi-omics data is revolutionizing the way we understand disease,” said Steve Barnard, Illumina Chief Technology Officer. “By combining Illumina's expertise in genomics data and analytics with NVIDIA's powerful AI platform, pharmaceutical and biotech companies can unlock their multi-omics data to uncover innovative insights and develop life-saving treatments. We aim to improve success rates.”
Mayo Clinic's AI-powered digital pathology
Pathology is an important and historically time-consuming technique that clinicians use to diagnose and determine treatment for many types of cancer and other serious and complex health conditions. It's a manual process. Mayo Clinic's digital pathology platform is built with an autonomous robotic lab and advanced imaging technology, consisting of 20 million full-slide images and 10 million relevant patient records that enable the creation of foundational models. Provides rich and unique datasets.
Mayo Clinic and NVIDIA will significantly accelerate the development of the next generation of basic pathology models. Mayo Clinic is using the newly available NVIDIA DGX™ Blackwell system (based on the NVIDIA Blackwell architecture and offering 1.4 TB of GPU memory per system, ideal for processing full slide datasets in digital pathology) and NVIDIA is planning to introduce MONAI, its healthcare imaging platform.
Mayo Clinic and NVIDIA are pioneering this research, which is fundamental to future AI applications in drug discovery and personalized diagnostics and therapy. The companies will continue to expand their collaboration with Mayo's clinical and AI expertise, NVIDIA Cosmos Nemotron vision language model and NIM microservices to deliver more personalized healthcare experiences with predictive and efficient treatment strategies. We will continue to provide it.
Augmenting Open Science Biology AI Models with Arc Institute
Arc Institute, a Palo Alto, California-based research organization working at the intersection of biology and machine learning, is collaborating with NVIDIA to develop and share powerful AI models and tools that accelerate biomedical discovery. I am.
Arc's biology and machine learning researchers are collaborating with NVIDIA engineers to expand the potential of fundamental biological models that can be generalized across different modalities, such as DNA, RNA, and proteins, increasing complexity and disease. We are applying this to drug discovery and synthetic biology across multiple scales. such as evolutionary research.
As part of the collaboration, NVIDIA provided large-scale model development expertise to Arc Institute. The NVIDIA BioNeMo platform running on NVIDIA DGX Cloud enables easy-to-use and optimized training. NVIDIA NIM Microservices and Blueprints.
